BidaskClub upgraded shares of Simulations Plus (NASDAQ:SLP) from a buy rating to a strong-buy rating in a research note published on Saturday morning.

Other research analysts have also recently issued research reports about the company. Zacks Investment Research raised Simulations Plus from a hold rating to a buy rating and set a $20.00 price objective on the stock in a research report on Saturday, July 21st. ValuEngine cut Simulations Plus from a strong-buy rating to a buy rating in a research report on Wednesday, July 11th.

SLP stock traded down $0.40 during midday trading on Friday, hitting $20.23. The company’s stock had a trading volume of 36,542 shares, compared to its average volume of 67,698. Simulations Plus has a 1 year low of $14.25 and a 1 year high of $23.95. The stock has a market cap of $351.29 million, a P/E ratio of 50.57 and a beta of -0.81.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, November 8th. Shareholders of record on Thursday, November 1st will be given a $0.06 dividend. The ex-dividend date is Wednesday, October 31st. This represents a $0.24 annualized dividend and a yield of 1.19%. Simulations Plus’s dividend payout ratio is currently 70.59%.

In other Simulations Plus news, Director Walter S. Woltosz sold 18,500 shares of the business’s stock in a transaction on Thursday, September 27th. The stock was sold at an average price of $19.92, for a total value of $368,520.00. Following the transaction, the director now owns 5,417,908 shares of the company’s stock, valued at $107,924,727.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 33.45% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Schwab Charles Investment Management Inc. lifted its position in shares of Simulations Plus by 16.3% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 22,688 shares of the technology company’s stock valued at $505,000 after buying an additional 3,188 shares during the last quarter. Bank of Montreal Can lifted its position in shares of Simulations Plus by 59.8% during the 3rd quarter. Bank of Montreal Can now owns 13,366 shares of the technology company’s stock valued at $270,000 after buying an additional 5,004 shares during the last quarter. MetLife Investment Advisors LLC purchased a new position in shares of Simulations Plus during the 2nd quarter valued at $129,000. Raymond James & Associates lifted its position in shares of Simulations Plus by 14.5% during the 2nd quarter. Raymond James & Associates now owns 49,615 shares of the technology company’s stock valued at $1,104,000 after buying an additional 6,267 shares during the last quarter. Finally, Stanley Laman Group Ltd. lifted its position in shares of Simulations Plus by 11.0% during the 2nd quarter. Stanley Laman Group Ltd. now owns 68,585 shares of the technology company’s stock valued at $1,526,000 after buying an additional 6,812 shares during the last quarter. 35.76% of the stock is currently owned by hedge funds and other institutional investors.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), and pharmacodynamics of drugs administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments, which measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.

Featured Article: What is a Leveraged Buyout (LBO)?

Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.